CA - Avicanna expands partnership with Viola Brands

• Avicanna ( OTCQX:AVCNF ) has entered into a new sub-license agreement with VB Brands California and Player Holdings to exclusively commercialize its Viola-branded products in the United Kingdom territory where the company has entered into a sub-licensing agreement with Vertical Pharma Resources.
• Starting late Q1 2023, Viola’s purpose-driven vision, rooted in social equity and social justice will be available to patients in the UK through the exclusive licensing agreement.
• To facilitate the expansion, Avicanna has entered a sub-licensing agreement with IPS Pharma, a local pharmaceutical distribution company with more than 20 years of experience with unlicensed medicines to support the launch of the product offerings.
• The initial products will be manufactured in the UK under GMP guidelines and distributed through IPS’ Pharma’s existing network of pharmacies via medical prescription under the Special Access Program.
• "We are also looking forward to building new relationships and potential collaborations with the medical community in the U.K. as we have in other markets,” stated Aras Azadian.

For further details see: